Cytosorbents (CTSO) Tax Provisions (2012 - 2025)

Cytosorbents (CTSO) has reported Tax Provisions for 12 consecutive years, with -$1.4 million the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Tax Provisions rose 16.91% year-over-year to -$1.4 million; the trailing twelve-month figure through Dec 2025 stood at -$3.5 million (down 39.62% YoY), and the FY2025 full-year result was -$1.8 million, down 6.8% from the prior year.
• Tax Provisions retreated to -$1.4 million in Q4 2025 per CTSO's latest filing, from -$401000.0 in the prior quarter.
• Across five years, Tax Provisions topped out at -$401000.0 in Q3 2025 and bottomed at -$1.7 million in Q4 2024.
• Historically, Tax Provisions has averaged -$1.0 million across 5 years, with a median of -$953162.0 in 2022.
• The sharpest annual moves came in 2021 and 2024: Tax Provisions jumped 34.7% in 2021, then plunged 107.81% in 2024.
• Over 5 years, Tax Provisions stood at -$736003.0 in 2021, then tumbled by 48.45% to -$1.1 million in 2022, then increased by 25.52% to -$813739.0 in 2023, then slumped by 107.81% to -$1.7 million in 2024, then climbed by 16.91% to -$1.4 million in 2025.
• According to Business Quant data, Tax Provisions over the past three periods registered -$1.4 million, -$401000.0, and -$1.7 million for Q4 2025, Q3 2025, and Q4 2024 respectively.